NIH R01 · 2024
Project Abstract Frontotemporal lobar degeneration (FTLD) is a family of neurodegenerative proteinopathies with no treatment to cure or slow disease progression. Clinical trials for FTLD are hamstrung by the limited biomarkers in cerebrospinal fluid (CSF) or plasma for screening or prognosis of FTLD, due in part to the extensive clinical and pathological heterogeneity in FTLD. There are no in vivo biomarkers to classify the two major pathological forms of FTLD: FTLD due to tau (FTLD-tau) or TAR DNA-binding protein of 43 kDa (TDP-43; FTLD-TDP). Both FTLD-tau and FTLD-TDP can be sporadic or due to pathogenic mutations, and both subtypes are associated with several cognitive and motor…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.